Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

VALN

Valneva SE ADR

Dec 01 • 04:00PM ET

11.50

Dollar change -0.12
Percentage change -1.00	%

Healthcare • Biotechnology • France • NASD

Stock Detail • Compare Perf. • Options Chain • Save to Portfolio • Create Alert

Scroll to Statements

Index	-	P/E	-	EPS (ttm)	-1.74	Insider Own	0.38%	Shs Outstand	69.39M	Perf Week	-0.29%
Market Cap	798.28M	Forward P/E	-	EPS next Y	-0.54	Insider Trans	0.00%	Shs Float	69.12M	Perf Month	-2.42%
Income	-120.18M	PEG	-	EPS next Q	0.61	Inst Own	0.60%	Short Float / Ratio	0.02% / 1.64	Perf Quarter	-17.71%
Sales	234.79M	P/S	3.40	EPS this Y	97.62%	Inst Trans	-	Short Interest	0.01M	Perf Half Y	-1.76%
Book/sh	2.40	P/B	4.79	EPS next Y	-844.32%	ROA	-19.46%	Target Price	22.20	Perf Year	-18.53%
Cash/sh	2.61	P/C	4.40	EPS next 5Y	-	ROE	-73.19%	52W Range	9.07 - 17.05	Perf YTD	-9.56%
Dividend	-	P/FCF	-	EPS past 5Y	-50.45%	ROI	-38.82%	52W High	-32.53%	Beta	2.47
Dividend %	-	Quick Ratio	1.30	Sales past 5Y	45.34%	Gross Margin	18.75%	52W Low	26.84%	ATR	0.57
Employees	-	Current Ratio	1.47	Sales Q/Q	-73.74%	Oper. Margin	-60.79%	RSI (14)	41.88	Volatility	2.79% 4.84%
Optionable	No	Debt/Eq	1.23	EPS Q/Q	-143.13%	Profit Margin	-51.19%	Rel Volume	0.25	Prev Close	11.62
Shortable	Yes	LT Debt/Eq	0.86	Earnings	Nov 20 AMC	Payout	-	Avg Volume	7.14K	Price	11.50
Recom	1.00	SMA20	-7.57%	SMA50	-2.91%	SMA200	-8.72%	Volume	1,795	Change	-1.00%

Date	Action	Analyst	Rating Change	Price Target Change
Aug-03-22	Initiated	H.C. Wainwright	Buy	$34

Nov-27-23 01:00AM	EMA Accepts Valneva's Chikungunya Vaccine Marketing Authorization Application for Accelerated Assessment (GlobeNewswire)
Nov-15-23 01:30AM	Valneva Announces the Availability of Documentation for its Extraordinary General Meeting including Planned Changes to its Future Board of Directors (GlobeNewswire)
Nov-13-23 01:00AM	Valneva Reports Positive Pivotal Phase 3 Immunogenicity Data in Adolescents for its Single-Shot Chikungunya Vaccine Candidate (GlobeNewswire)
Nov-11-23 10:25AM	Valneva SE (NASDAQ:VALN) Q3 2023 Earnings Call Transcript (Insider Monkey)
Nov-10-23 01:00AM	Valneva Announces U.S. FDA Approval of World's First Chikungunya Vaccine, IXCHIQ (GlobeNewswire)
01:00AM	Loading…
Nov-09-23 01:00AM	Valneva Reports Nine-Month 2023 Financial Results and Provides Corporate Updates (GlobeNewswire) +6.67%
Nov-07-23 01:00AM	Valneva to Present and Hold Investor Meetings at the Jefferies London Healthcare Conference (GlobeNewswire)
Nov-06-23 02:30AM	VALNEVA Declaration of shares and voting rights: October 31, 2023 (GlobeNewswire)
Oct-25-23 12:15PM	Valneva Submits Chikungunya Vaccine Marketing Application to EMA and Announces CHMP Accelerated Assessment (GlobeNewswire) +6.72%
Oct-11-23 11:45AM	Valneva to Present on Chikungunya at Several Leading Scientific Conferences (GlobeNewswire)
Oct-05-23 02:30AM	VALNEVA - Declaration of shares and voting rights: September 30, 2023 (GlobeNewswire)
Sep-27-23 09:33AM	Valneva SE (NASDAQ:VALN) Q2 2023 Earnings Call Transcript (Insider Monkey)
Sep-25-23 01:00AM	Valneva Announces New IXIARO® Supply Contract with the U.S. Government Worth a Minimum of $32 Million (GlobeNewswire)
Sep-21-23 01:00AM	Valneva Reports Half Year 2023 Financial Results and Provides Corporate Updates (GlobeNewswire)
Sep-07-23 01:00AM	Valneva and Pfizer Report Positive Pediatric and Adolescent Phase 2 Booster Results for Lyme Disease Vaccine Candidate (GlobeNewswire)
02:30AM	Loading…
Sep-06-23 02:30AM	VALNEVA Declaration of shares and voting rights: August 31, 2023 (GlobeNewswire)
Aug-31-23 01:00PM	Valneva to Participate in Investor Conferences in the United States and Europe in September 2023 (GlobeNewswire)
Aug-29-23 01:00AM	Health Canada Accepts Valnevas Chikungunya Vaccine License Application for Review (GlobeNewswire)
Aug-28-23 01:00AM	Valneva Reports Positive Initial Phase 3 Safety Data in Adolescents for its Single-Shot Chikungunya Vaccine Candidate (GlobeNewswire)
Aug-17-23 01:00AM	Valneva Announces Extension of Existing Loan Agreement (GlobeNewswire)
Aug-14-23 01:00AM	Valneva Announces PDUFA Date Extension for Chikungunya Virus Vaccine Candidate (GlobeNewswire)
Aug-03-23 02:30AM	VALNEVA Declaration of shares and voting rights - July 31, 2023 (GlobeNewswire)
Jul-05-23 02:30AM	VALNEVA - Declaration of shares and voting rights: June 30, 2023 (GlobeNewswire)
Jun-22-23 01:00AM	Valneva Supervisory Board Recommends Transition from a Two-Tier Governance Model to a Board of Directors (GlobeNewswire)
Jun-21-23 12:15PM	Valneva Announces Successful Outcome of its AGM and the Appointment of Pfizers Former Vaccine R&D Head to its Supervisory Board (GlobeNewswire)
Jun-13-23 01:00AM	Valneva Announces Publication of its Chikungunya Vaccine Candidate Phase 3 Data in The Lancet (GlobeNewswire)
Jun-07-23 02:00AM	VALNEVA - Declaration of shares and voting rights: May 31, 2023 (GlobeNewswire)
May-31-23 01:15AM	Valneva to Present and Hold Investor Meetings at Upcoming Conferences in June (GlobeNewswire)
01:00AM	Valneva Announces the Availability of Documentation for its Shareholder Meeting (GlobeNewswire)
May-30-23 01:00AM	Valneva Files for Chikungunya Vaccine Authorization with Health Canada (GlobeNewswire)
12:00PM	Loading…
May-04-23 12:00PM	VALNEVA - Declaration of shares and voting rights - April 30, 2023 (GlobeNewswire) +21.84%
01:00AM	Valneva Reports First Quarter 2023 Financial Results and Provides Corporate Updates (GlobeNewswire)
Apr-06-23 02:00AM	VALNEVA - Declaration of shares and voting rights - March 31, 2023 (GlobeNewswire)
Mar-31-23 01:00AM	Valneva Announces Filing of 2022 Universal Registration Document and US Form 20-F (GlobeNewswire)
Mar-30-23 01:00AM	Valneva to Present on its Chikungunya Vaccine Candidate and Host a Roundtable at the 23rd World Vaccine Congress in Washington D.C. (GlobeNewswire)
Mar-23-23 02:00AM	Valneva Reports Full Year 2022 Results and Provides Corporate Updates (GlobeNewswire)
Mar-06-23 02:00AM	VALNEVA - Declaration of shares and voting rights - February 28, 2023 (GlobeNewswire)
Mar-02-23 01:00AM	Valneva Provides Clinical and Regulatory Updates for its COVID-19 Vaccine VLA2001 (GlobeNewswire)
Mar-01-23 11:45AM	Valneva to Present at the Cowen 43rd Annual Healthcare Conference (GlobeNewswire)
Feb-20-23 01:00AM	FDA Accepts Valnevas Chikungunya Vaccine License Application for Priority Review (GlobeNewswire)
Feb-17-23 01:00AM	Pfizer and Valneva Issue Update on Phase 3 Clinical Trial Evaluating Lyme Disease Vaccine Candidate VLA15 (GlobeNewswire) -7.10%
Feb-16-23 01:00AM	Valneva Reports Full Year 2022 Revenue and Cash, Provides First 2023 Guidance (GlobeNewswire) +5.85%
Feb-14-23 01:00AM	Valneva Completes Enrollment for Adolescent Phase 3 Trial of Single-Shot Chikungunya Vaccine Candidate (GlobeNewswire)
Feb-03-23 12:00PM	VALNEVA Declaration of shares and voting rights - January 31, 2023 (GlobeNewswire)
Jan-19-23 12:00PM	VALNEVA - Declaration of shares and voting rights: Status on December 31, 2022 (corrected data) and January 4, 2023 (GlobeNewswire)
Jan-05-23 12:00PM	VALNEVA - Declaration of shares and voting rights: December 31, 2022 (GlobeNewswire)
Dec-30-22 12:30PM	Valneva Reports Further Heterologous Booster Data for its inactivated COVID-19 vaccine (GlobeNewswire)
Dec-23-22 11:04AM	Valneva Concludes FDA Regulatory Submission For One-Shot Chikungunya Vaccine (Benzinga)
02:41AM	Tesla, Meta Platforms, and Valneva rise premarket (Investing.com)
01:00AM	Valneva Completes BLA Submission to U.S. FDA for its Single-Shot Chikungunya Vaccine Candidate (GlobeNewswire)
Dec-21-22 11:45AM	Valneva to Conduct Investor Meetings during the J.P. Morgan Healthcare Conference and Oddo BHF Forum (GlobeNewswire)
Dec-08-22 10:21AM	France Health Body Advises Unfavorable Opinion Regarding Valneva's COVID-19 Vaccine (Benzinga)
Dec-06-22 08:16AM	Valneva (VALN) Up on Antibody Persistence Data on Chikungunya Jab (Zacks) -6.09%
01:00AM	Valneva Hosts Investor Day in New York City (GlobeNewswire)
Dec-05-22 12:00PM	VALNEVA - Declaration of shares and voting rights: November 30, 2022 (GlobeNewswire) +5.01%
01:00AM	Valneva Reports Positive 12-Month Antibody Persistence Data for Single-Shot Chikungunya Vaccine Candidate (GlobeNewswire)
Dec-02-22 10:54AM	Valneva (VALN) Up on 6-Month Lyme Disease Jab Persistence Data (Zacks)
Dec-01-22 04:13PM	Will A Pfizer-Partnered Vaccine Help Valneva Stock Buck Its Recent Downtrend? (Investor's Business Daily) +7.58%
01:00AM	Valneva and Pfizer Report Six-Month Antibody Persistence Data in Children and Adults for Lyme Disease Vaccine Candidate (GlobeNewswire)
Nov-29-22 12:00PM	Valneva to Host Investor Day in New York City (GlobeNewswire)
Nov-17-22 01:00AM	Valneva Appoints Dipal Patel as Chief Commercial Officer (GlobeNewswire)
Nov-16-22 09:55AM	Wall Street Analysts See a 65% Upside in Valneva SE Sponsored ADR (VALN): Can the Stock Really Move This High? (Zacks)
Nov-10-22 01:00AM	Valneva Reports Nine-Month 2022 Results and Provides Corporate Updates (GlobeNewswire)
Nov-07-22 11:45AM	Valneva to Present and Hold Investor Meetings at the Jefferies London Healthcare Conference (GlobeNewswire)
Nov-04-22 01:00PM	VALNEVA - Declaration of shares and voting rights: October 31, 2022 (GlobeNewswire)
Oct-12-22 12:00PM	All You Need to Know About Valneva SE Sponsored ADR (VALN) Rating Upgrade to Buy (Zacks)
Oct-10-22 01:00AM	Valneva to Present on its Single-Shot Chikungunya Vaccine Candidate at Leading Scientific Conferences (GlobeNewswire)
Oct-07-22 12:00PM	VALNEVA - Declaration of shares and voting rights: Interim status at October 4, 2022 (and information at September 30, 2022) (GlobeNewswire)
Oct-04-22 04:00PM	Valneva Announces Closing of Upsized 102.9 Million Global Offering (GlobeNewswire) +13.68%
Sep-30-22 01:11AM	Valneva Announces Pricing of 102.9 Million Global Offering of American Depositary Shares and Ordinary Shares (GlobeNewswire)
Sep-28-22 05:43PM	Valneva Announces Launch of Approximately $40 Million in a Proposed Global Offering of American Depositary Shares and Ordinary Shares (GlobeNewswire) +6.07%
Sep-26-22 12:39PM	Valneva (VALN) Stock Down 66% in the Past 6 Months: Here's Why (Zacks)
08:06AM	Valneva Tries Reviving COVID-19 Vaccine Play As It Talks With Potential Partner For An Updated Shot (Benzinga)
01:26AM	UPDATE 2-Valneva in talks with potential partner on second-gen COVID-19 vaccines (Reuters)
01:00AM	Valneva Provides Further Update on its COVID-19 Activities (GlobeNewswire)
Sep-19-22 07:42AM	Valneva Cuts Ties With Its COVID-19 Vaccine Manufacturing Partner In Germany (Benzinga) -19.00%
Sep-16-22 04:30PM	Valneva and IDT Biologika Agree on Termination of their COVID-19 Collaboration (GlobeNewswire)
Sep-08-22 01:00AM	Valneva and VBI Vaccines Announce European Partnership for Marketing and Distribution of PreHevbri® (GlobeNewswire)
Sep-06-22 01:00AM	Valneva Announces Publication of its COVID-19 Vaccine Phase 3 Data in The Lancet Infectious Diseases (GlobeNewswire) -7.37%
Sep-05-22 12:00PM	VALNEVA - Declaration of shares and voting rights: August 31, 2022 (GlobeNewswire)
Aug-29-22 09:03AM	Valneva Posts Additional Encouraging Data From COVID-19 Booster Trial (Benzinga)
01:00AM	Valneva Reports Further Positive Phase 3 Immunogenicity and the First Heterologous Booster Results for its Inactivated, Adjuvanted COVID-19 Vaccine VLA2001 (GlobeNewswire)
Aug-23-22 11:45AM	Valneva Confirms WHO Recommendations for its Inactivated COVID-19 Vaccine (GlobeNewswire)
Aug-18-22 12:00PM	Valneva Initiates Rolling Submission of FDA Biologics License Application for its Single-Shot Chikungunya Vaccine Candidate (GlobeNewswire)
08:11AM	US Dept of Defense Ends Vaccine Supply Pact With Valneva For Viral Brain Infection (Benzinga)
01:00AM	Valneva Provides Update on IXIARO® Supply Contract with U.S. Department of Defense (GlobeNewswire)
Aug-15-22 01:00AM	Valneva Establishes an At-the-Market (ATM) Program on Nasdaq (GlobeNewswire)
Aug-11-22 07:07AM	Valneva Cuts FY22 COVID-19 Vaccine Sales Outlook, Needs Funding To Invest In Next-Gen COVID-19 Shot (Benzinga)
01:31AM	Valneva cuts full-year outlook on lower COVID-19 vaccine sales (Reuters)
01:00AM	Valneva Reports H1 2022 Results and Provides Corporate Updates (GlobeNewswire)
Aug-08-22 05:19PM	Pfizer, Valneva begin major test of first possible Lyme vaccine in 20 years (MarketWatch)
04:53PM	Pfizer tests vaccine to fend off spread of tick-borne Lyme disease (Financial Times)
04:45PM	Pfizer and Valneva Initiate Phase 3 Study of Lyme Disease Vaccine Candidate VLA15 (Business Wire)
01:56PM	Lyme Disease And Climate Change Reinvigorates Valneva's Vaccine Efforts After COVID Shot Disappointment (Benzinga)
02:00AM	FOCUS-Climate change puts Lyme disease in focus for France's Valneva after COVID blow (Reuters)
Aug-04-22 12:00PM	VALNEVA - Declaration of shares and voting rights - July 31, 2022 (GlobeNewswire) +6.28%
Aug-01-22 11:45AM	Valneva Confirms Amendment of Advance Purchase Agreement with European Commission for Valnevas Inactivated COVID-19 Vaccine (GlobeNewswire) -5.35%
Jul-20-22 12:49PM	UPDATE 1-EU drops nearly all of its order for Valneva COVID vaccine (Reuters) -12.25%
12:00PM	European Commission Approves Purchase Agreement Amendment for Valnevas Inactivated COVID-19 Vaccine (GlobeNewswire)
Jul-05-22 12:00PM	VALNEVA - Declaration of shares and voting rights - June 30, 2022 (GlobeNewswire) +10.40%

Valneva SE is a specialty vaccine company. The firm focuses on the development and commercialization of prophylactic vaccines for infectious diseases with significant unmet medical need. It takes a highly specialized and targeted approach to vaccine development and then applies its deep understanding of vaccine science to develop prophylactic vaccines addressing these diseases. It operates through the following segments: Commercialized products, COVID, Vaccine candidates and Technologies and services. The Commercialized products segment markets vaccines, currently IXIARO and DUKORAL vaccines, as well as third-party products. The COVID segment engages in the development, manufacturing and distribution related to COVID-19 vaccine candidate, VLA2001. The Vaccine candidates segment engages in proprietary research and development programs aiming to generate new approvable products in order to generate future cash flows from product sales or from commercialization through partnering with pharmaceutical companies, excluding COVID-19 vaccine candidate, VLA2001. The Technologies and services segment provides services and inventions at a commercialization stage. The company was founded on April 7, 1999 and is headquartered in Saint-Herblain, France.

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

VALN

Valneva SE ADR

Upgrade your FINVIZ experience